A previous meta‐analysis of 14 studies found that among patients with early‐stage hormone receptor‐positive BC, compared to the HER2‐zero BC, the HER2‐low BC had significantly favorable OS, DFS, and relapse‐free survival (RFS).26 This evidence concerns the gene ERBB2 and breast cancer.